Marinus Pharmaceuticals, Inc. (MRNS) Financials

MRNS Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 170.9 million 154.1 million
2023-09-30 200.8 million 146.3 million
2023-06-30 201.2 million 143.9 million
2023-03-31 226.8 million 141.7 million

MRNS Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -27.0 million 3.9 million
2023-09-30 -25.3 million 4.0 million
2023-06-30 -24.4 million 3.9 million
2023-03-31 -41.5 million 3.7 million

MRNS Net Income

No data available :(

MRNS Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 150.3 million - 774000
2023-09-30 176.4 million - 1.7 million
2023-06-30 175.3 million 68.1 million 1.8 million
2023-03-31 199.2 million 71.5 million 2.1 million

MRNS Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 56.7 million
2023-09-30 53.9 million
2023-06-30 52.6 million
2023-03-31 51.8 million

MRNS Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 34000 26.3 million 15.4 million -
2023-09-30 85000 23.7 million 14.9 million -
2023-06-30 - 21.4 million 15.7 million -
2023-03-31 - 27.9 million 15.2 million -

MRNS Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 7.2 million 1.0 million
2023-09-30 7.3 million 455000
2023-06-30 6.1 million 386000
2023-03-31 10.4 million 206000

MRNS

Price: $1.51

52 week price:
1.20
11.26

Earnings Per Share: -2.63 USD

P/E Ratio: -3.59

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Volume: 214200

Ebitda: -19.9 million

Market Capitalization: 475.4 million

Links: